INVESTIGADORES
GIAMBARTOLOMEI Guillermo Hernan
artículos
Título:
The vaccine candidate BLSOmp31 protects mice against Brucella canis infection.
Autor/es:
CLAUSSE M., DÍAZ A. G., GHERSI G, ZYLBERMAN V., CASSATARO J., GIAMBARTOLOMEI G. H., GOLDBAUMB F. A., ESTEIN S. M.
Revista:
VACCINE
Editorial:
ELSEVIER SCI LTD
Referencias:
Lugar: Amsterdam; Año: 2013 vol. 31 p. 6129 - 6135
ISSN:
0264-410X
Resumen:
Canine brucellosis represents a major reproductive problem worldwide and it is considered a zoonotic
disease. New approaches are therefore urgently needed to develop an effective and safe immunization
strategy against Brucella canis. In the present study, BALB/c mice were subcutaneously immunized with
the recombinant chimera rBLSOmp31 formulated in different adjuvants. The different strategies induced
a vigorous immunoglobulin G (IgG) response, with high titers of IgG1 as well as IgG2. Besides, spleen
cells from rBLSOmp31-immunized mice produced gamma interferon and IL-4, suggesting the induction
of a mixed Th1?Th2. Vaccination with rBLSOmp31-IFA formulation provided the best protection levels
comparable with that given by control vaccines. None of the immunization strategies induced serological
interference in diagnosis. Hitherto, this is the first report that a recombinant vaccine confers protection
against B. canis in mice.
the recombinant chimera rBLSOmp31 formulated in different adjuvants. The different strategies induced
a vigorous immunoglobulin G (IgG) response, with high titers of IgG1 as well as IgG2. Besides, spleen
cells from rBLSOmp31-immunized mice produced gamma interferon and IL-4, suggesting the induction
of a mixed Th1?Th2. Vaccination with rBLSOmp31-IFA formulation provided the best protection levels
comparable with that given by control vaccines. None of the immunization strategies induced serological
interference in diagnosis. Hitherto, this is the first report that a recombinant vaccine confers protection
against B. canis in mice.
Brucella canis. In the present study, BALB/c mice were subcutaneously immunized with
the recombinant chimera rBLSOmp31 formulated in different adjuvants. The different strategies induced
a vigorous immunoglobulin G (IgG) response, with high titers of IgG1 as well as IgG2. Besides, spleen
cells from rBLSOmp31-immunized mice produced gamma interferon and IL-4, suggesting the induction
of a mixed Th1?Th2. Vaccination with rBLSOmp31-IFA formulation provided the best protection levels
comparable with that given by control vaccines. None of the immunization strategies induced serological
interference in diagnosis. Hitherto, this is the first report that a recombinant vaccine confers protection
against B. canis in mice.B. canis in mice.